

Elke Pogge von Strandmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9472547/publications.pdf>

Version: 2024-02-01

38
papers

2,753
citations

331538

21
h-index

330025

37
g-index

38
all docs

38
docs citations

38
times ranked

4782
citing authors

#	ARTICLE	IF	CITATIONS
1	Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. <i>Oncolmmunology</i> , 2016, 5, e1071008.	2.1	545
2	Extracellular vesicle measurements with nanoparticle tracking analysis – An accuracy and repeatability comparison between NanoSight NS300 and ZetaView. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1596016.	5.5	318
3	Human Leukocyte Antigen-B-Associated Transcript 3 Is Released from Tumor Cells and Engages the NKp30 Receptor on Natural Killer Cells. <i>Immunity</i> , 2007, 27, 965-974.	6.6	284
4	Dendritic Cells Release HLA-B-Associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function. <i>PLoS ONE</i> , 2008, 3, e3377.	1.1	207
5	The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 24.	1.3	187
6	Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. <i>Blood</i> , 2013, 121, 3658-3665.	0.6	184
7	Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell – Activating Receptor NKp30. <i>Cancer Research</i> , 2014, 74, 3429-3440.	0.4	169
8	Tumor – Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure. <i>Trends in Cancer</i> , 2017, 3, 137-148.	3.8	85
9	Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. <i>Blood</i> , 2013, 121, 812-821.	0.6	80
10	Cancer-derived extracellular vesicles: friend and foe of tumour immunosurveillance. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2018, 373, 20160481.	1.8	68
11	Hodgkin Lymphoma-Derived Extracellular Vesicles Change the Secretome of Fibroblasts Toward a CAF Phenotype. <i>Frontiers in Immunology</i> , 2018, 9, 1358.	2.2	57
12	Multi-platform Affinity Proteomics Identify Proteins Linked to Metastasis and Immune Suppression in Ovarian Cancer Plasma. <i>Frontiers in Oncology</i> , 2019, 9, 1150.	1.3	47
13	RIG-I activation induces the release of extracellular vesicles with antitumor activity. <i>Oncolmmunology</i> , 2016, 5, e1219827.	2.1	44
14	Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53. <i>Theranostics</i> , 2019, 9, 6047-6062.	4.6	43
15	CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, <i>in vitro</i> . <i>Oncotarget</i> , 2016, 7, 30523-30535.	0.8	43
16	Role of Exosomes Released by Dendritic Cells and/or by Tumor Targets: Regulation of NK Cell Plasticity. <i>Frontiers in Immunology</i> , 2014, 5, 91.	2.2	38
17	Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment. <i>Theranostics</i> , 2019, 9, 6601-6617.	4.6	36
18	Antigen Loss Variants: Catching Hold of Escaping Foes. <i>Frontiers in Immunology</i> , 2017, 8, 175.	2.2	35

#	ARTICLE	IF	CITATIONS
19	The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2018, 7, 295.	1.0	30
20	Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation. <i>Oncolmmunology</i> , 2017, 6, e1339854.	2.1	29
21	The Role of Extracellular HSP70 in the Function of Tumor-Associated Immune Cells. <i>Cancers</i> , 2021, 13, 4721.	1.7	27
22	Phosphoproteomics identify arachidonic-acid-regulated signal transduction pathways modulating macrophage functions with implications for ovarian cancer. <i>Theranostics</i> , 2021, 11, 1377-1395.	4.6	22
23	Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer. <i>Trends in Molecular Medicine</i> , 2014, 20, 72-82.	3.5	20
24	Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia. <i>Oncolmmunology</i> , 2016, 5, e1211220.	2.1	18
25	Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. <i>Blood</i> , 2018, 132, 2040-2052.	0.6	17
26	Extracellular vesicles released from chronic lymphocytic leukemia cells exhibit a disease relevant mRNA signature and transfer mRNA to bystander cells. <i>Haematologica</i> , 2017, 102, e100-e103.	1.7	15
27	Kinesin-5 Blocker Monastrol Protects Against Bortezomib-Induced Peripheral Neurotoxicity. <i>Neurotoxicity Research</i> , 2017, 32, 555-562.	1.3	14
28	Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2189.	1.8	14
29	IFN-Gamma and TNF-Alpha as a Priming Strategy to Enhance the Immunomodulatory Capacity of Secretomes from Menstrual Blood-Derived Stromal Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12177.	1.8	13
30	NKp30 and its ligands: emerging players in tumor immune evasion from natural killer cells. <i>Annals of Translational Medicine</i> , 2015, 3, 314.	0.7	12
31	The Oncoprotein SKI Acts as A Suppressor of NK Cell-Mediated Immunosurveillance in PDAC. <i>Cancers</i> , 2020, 12, 2857.	1.7	11
32	The Immunomodulatory Signature of Extracellular Vesicles From Cardiosphere-Derived Cells: A Proteomic and miRNA Profiling. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 321.	1.8	11
33	Shipping Drug Resistance: Extracellular Vesicles in Ovarian Cancer. <i>Trends in Molecular Medicine</i> , 2016, 22, 741-743.	3.5	9
34	Molecular Determinants for RNA Release into Extracellular Vesicles. <i>Cells</i> , 2021, 10, 2674.	1.8	8
35	DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies. <i>Frontiers in Genetics</i> , 2015, 6, 11.	1.1	6
36	Beyond the Extracellular Vesicles: Technical Hurdles, Achieved Goals and Current Challenges When Working on Adipose Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3362.	1.8	6

#	ARTICLE	IF	CITATIONS
37	The more the better – determining the optimal range when performing single-vesicle phenotyping. Trillium Extracellular Vesicles, 2021, 1, 26-33.	0.1	1
38	RNAs and extracellular vesicles - Keeping up the appearances. Trillium Extracellular Vesicles, 2021, 1, 12-15.	0.1	0